Halle Berry and Women's HRT: How Her Menopause Advocacy Compares to Other Public Figures

Why Halle Berry's Menopause Advocacy Stands Out

Berry's public engagement with menopause and HRT goes beyond personal disclosure. She has used her platform for legislative action, brand building, and clinical education in ways that distinguish her from most celebrity health advocates. Her 2024 testimony before the U.S. Senate Appropriations Subcommittee called for increased NIH funding for menopause research, citing the fact that fewer than 1% of NIH grants historically addressed menopause [1].

From Misdiagnosis to Advocacy

Berry has stated in multiple interviews that she was initially misdiagnosed as prediabetic when she first experienced perimenopausal symptoms in her early 40s. That experience of diagnostic delay mirrors a pattern documented in the medical literature. A 2023 survey published in Menopause found that the median time from symptom onset to menopause diagnosis exceeded 4 years, and roughly 40% of women consulted three or more physicians before receiving a correct diagnosis [2]. Berry has cited this personal timeline repeatedly as motivation for her advocacy.

Congressional Testimony and the Menopause Act

In June 2024, Berry testified alongside physicians and researchers in support of the Advancing Menopause Care and Mid-Life Women's Health Act, a bipartisan bill that would direct federal resources toward menopause research, provider training, and public education. During her testimony, Berry described menopause as a condition that "affects every single woman who has the privilege of aging" and called the research gap "unacceptable." No other celebrity in recent memory has taken menopause advocacy to the federal legislative level with this degree of specificity.

Hormone Pellet Therapy: What Berry Uses

Berry has publicly discussed her use of bioidentical hormone pellet therapy, a subcutaneous delivery system in which compressed estradiol (and sometimes testosterone) pellets are inserted beneath the skin of the hip or buttock. Each pellet delivers a steady-state dose over approximately 3 to 5 months. A 2019 review in Climacteric reported that subcutaneous estradiol pellets produce stable serum estradiol levels between 60 and 100 pg/mL in most patients, with fewer fluctuations than oral or transdermal formulations [3]. The Endocrine Society and The Menopause Society do not list pellets among their first-line recommended delivery methods, citing limited long-term safety data and concerns about supraphysiologic hormone levels in some patients. Berry's public endorsement has brought pellet therapy into mainstream conversation, though clinical guidelines continue to favor FDA-approved transdermal patches, oral formulations, and vaginal preparations as initial options [4].

How Berry Compares to Other Celebrity Menopause Advocates

Several high-profile women have spoken publicly about menopause and HRT in recent years. Each has taken a distinct approach, ranging from product development to personal memoir to media-driven education.

Naomi Watts: The Brand Builder

Naomi Watts entered perimenopause in her late 30s and was told she might not be able to conceive again. She launched Stripes in 2022, a consumer brand offering menopause-targeted skincare, supplements, and vaginal moisturizers. Watts has spoken about using HRT herself, though she focuses more on normalizing the conversation than on specific clinical details. Her approach is primarily commercial and destigmatizing, positioned around the idea that menopause products should be as visible and accessible as any other wellness category.

Where Berry leans into policy and clinical specifics, Watts leans into consumer access. Both approaches address the same underlying problem: that menopause has been undertreated and under-discussed. The difference is the vector. Berry pushes for systemic change through legislation. Watts pushes for cultural normalization through retail presence.

Oprah Winfrey: The Media Amplifier

Oprah Winfrey disclosed in late 2024 that she uses HRT for menopause symptoms, making the announcement during a period when she was also discussing her use of GLP-1 receptor agonist medication for weight management. Winfrey's disclosure reached an audience of millions and generated significant media coverage. Her framing was personal and emotional, describing the relief she experienced after starting HRT and expressing frustration that she had not been offered it sooner.

Winfrey's role is that of a megaphone. Her platform is unmatched in reach, and her willingness to discuss HRT publicly has likely influenced patient-provider conversations across the country. A 2024 analysis in JAMA Internal Medicine noted that celebrity health disclosures can produce measurable spikes in prescription volumes and search interest within 72 hours of a public statement [5]. Winfrey differs from Berry in that her advocacy is experiential rather than legislative.

Michelle Obama: The Conversation Starter

Michelle Obama discussed her experience with hot flashes and hormonal changes in her 2020 Michelle Obama Podcast, describing a hot flash she experienced on Marine One. Her disclosure was notable for its specificity and for the audience it reached. Obama did not disclose whether she uses HRT, but her willingness to describe symptoms in detail gave many women a vocabulary for their own experiences.

Obama's contribution is conversational rather than clinical. She opened a door without prescribing a path through it. For a former First Lady to discuss hot flashes publicly helped reposition menopause from a private medical event to a public health topic.

Drew Barrymore: The Emotional Narrator

Drew Barrymore has discussed perimenopause and menopause on her daytime talk show, often with visible emotion. She has described mood changes, sleep disruption, and the psychological weight of hormonal transition. Barrymore's approach is confessional and empathetic, creating space for women who feel isolated by their symptoms.

Barrymore has not disclosed specific HRT use publicly. Her value as an advocate is affective rather than informational. She normalizes the emotional experience of menopause without offering clinical direction.

A Framework for Comparing Celebrity HRT Advocacy

| Public Figure | Advocacy Type | HRT Disclosure | Primary Channel | Distinguishing Feature | |---|---|---|---|---| | Halle Berry | Legislative, clinical | Yes (pellet therapy) | Congressional testimony, interviews | Federal policy engagement | | Naomi Watts | Commercial, cultural | Yes (unspecified HRT) | Stripes brand, media | Consumer product development | | Oprah Winfrey | Experiential, media | Yes (unspecified HRT) | TV, social media | Unmatched audience reach | | Michelle Obama | Conversational | Not disclosed | Podcast, memoir | Normalizing symptom discussion | | Drew Barrymore | Emotional, empathetic | Not disclosed | Daytime TV | Affective storytelling |

The Clinical Evidence Behind HRT for Menopausal Women

Celebrity advocacy becomes meaningful when it drives women toward evidence-based treatment. The clinical literature supports HRT for symptomatic menopausal women who initiate therapy within 10 years of menopause onset or before age 60.

What the Guidelines Say

The 2022 Menopause Society position statement reaffirmed that the benefits of HRT outweigh the risks for most symptomatic women under 60 or within 10 years of menopause onset [4]. The Endocrine Society's 2019 guideline on menopausal HRT similarly endorses systemic estrogen therapy as the most effective treatment for vasomotor symptoms, with transdermal estradiol preferred in women at elevated thrombotic risk [6]. Both organizations recommend the lowest effective dose for the shortest appropriate duration, though they acknowledge that many women benefit from extended use [6].

Vasomotor Symptom Reduction

Estrogen therapy reduces hot flash frequency by 75% on average compared to placebo, according to a Cochrane review of 24 randomized controlled trials (N=3,329) [7]. This effect is consistent across oral, transdermal, and vaginal delivery systems. The Women's Health Initiative (WHI) estrogen-alone arm (N=10,739) demonstrated that conjugated equine estrogen reduced vasomotor symptoms significantly, with a hazard ratio of 0.77 for coronary heart disease in women aged 50 to 59 at enrollment [8].

Bone and Cardiovascular Considerations

The WHI reanalysis published in JAMA showed that women who initiated HRT between ages 50 and 59 had lower all-cause mortality compared to placebo (HR 0.69, 95% CI 0.51 to 0.94) [8]. Estrogen therapy also reduced hip fracture risk by 33% across all age groups in the WHI. The 2017 Endocrine Society scientific statement confirmed that HRT preserves bone mineral density and reduces vertebral and non-vertebral fracture risk in postmenopausal women [9].

These data support the position that Berry and other advocates occupy: HRT is not a fringe treatment. It is supported by decades of randomized trial evidence for appropriately selected patients.

Why Pellet Therapy Remains Controversial

Berry's specific choice of subcutaneous hormone pellets sits outside mainstream guideline recommendations, which creates a tension between her advocacy and the clinical consensus.

How Pellets Work

Hormone pellets are compounded formulations, typically containing crystalline estradiol (and sometimes testosterone), compressed into cylinders roughly the size of a grain of rice. A clinician inserts them subcutaneously, usually in the upper buttock, through a small incision under local anesthesia. The pellet dissolves slowly over 3 to 5 months, releasing hormone at a relatively constant rate [3].

Guideline Concerns

The Menopause Society's 2022 position statement notes that custom-compounded bioidentical hormones, including pellets, lack the regulatory oversight of FDA-approved products. Specific concerns include inconsistent dosing between batches, supraphysiologic estradiol levels (sometimes exceeding 300 pg/mL), and the inability to rapidly discontinue therapy if adverse effects occur, since the pellet cannot be easily removed once inserted [4].

The American College of Obstetricians and Gynecologists (ACOG) states that FDA-approved hormone therapy formulations are preferred over compounded products because of standardized manufacturing, proven bioavailability, and established safety profiles [10]. Dr. Stephanie Faubion, medical director of The Menopause Society, has noted: "There is no evidence that compounded bioidentical hormones are safer or more effective than FDA-approved formulations, and there are concerns about quality control."

Why Some Clinicians Still Use Pellets

Despite guideline skepticism, pellet therapy has a dedicated following among certain integrative and anti-aging practitioners. Proponents argue that the steady-state delivery avoids the peaks and troughs of oral dosing and that some patients report superior symptom control. A retrospective study of 300 women treated with subcutaneous estradiol and testosterone pellets reported that 87% experienced significant improvement in vasomotor symptoms, libido, and mood at 6 months, though the study lacked a placebo control group [3].

The gap between clinical experience reports and randomized trial evidence is the core of the pellet therapy debate. Berry's endorsement gives pellets visibility, but it does not resolve the evidence question.

The Broader Impact of Celebrity Menopause Advocacy

Celebrity disclosures about menopause and HRT have measurable effects on public behavior. They also carry risks.

The Positive Effects

Research from JAMA Network Open has documented that celebrity health disclosures increase screening rates, search volumes, and patient-provider discussions about disclosed conditions [5]. When a figure like Berry or Winfrey discusses HRT, women who might not have raised the topic with their physician gain a framework for doing so. This is particularly relevant given that a 2023 study found only 20% of OB-GYN residency programs included formal menopause medicine training [4], meaning many patients know more about HRT from media than from their doctors.

The Risks of Celebrity Health Advocacy

Celebrity endorsements can also lead to inappropriate treatment choices. A woman hearing Berry discuss pellet therapy may request pellets from her clinician without understanding the differences between compounded and FDA-approved products. The American Association of Clinical Endocrinology (AACE) has cautioned that celebrity-driven demand for specific formulations can create "prescribing pressure" on clinicians, particularly in direct-to-consumer telehealth settings where visit times are short [11].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and a principal investigator of the WHI, has stated: "Celebrity advocacy for menopause awareness is overwhelmingly positive, but women should work with their clinicians to choose FDA-approved therapies with proven safety records rather than selecting treatments based on what a public figure reports using."

Where the Conversation Goes From Here

The 2024 Senate hearing where Berry testified represents a potential inflection point. If the Advancing Menopause Care and Mid-Life Women's Health Act secures funding, it could support the first large-scale randomized trials comparing different HRT delivery systems, including pellets, in diverse populations. That evidence would either validate or undermine the empirical claims that pellet therapy advocates have made for decades.

The collective effect of Berry, Watts, Winfrey, Obama, and Barrymore is additive. Each reaches a different audience through a different medium. Berry brings legislative weight. Watts brings consumer products. Winfrey brings reach. Obama brings cultural authority. Barrymore brings emotional permission. Together, they have moved menopause from a whispered inconvenience to a public health priority receiving federal attention and research dollars.

Women considering HRT should discuss FDA-approved options with a board-certified physician, request baseline labs including serum estradiol, FSH, and a lipid panel, and review their personal and family history of breast cancer, cardiovascular disease, and venous thromboembolism before initiating therapy [6].